RESEARCH TRIANGLE PARK, N.C., July 13 /PRNewswire/ -- Nascent Pharmaceuticals, Inc. announced today that Joanna C. Horobin, M.D., has been appointed to its Board of Directors. Dr. Horobin is President and Chief Executive Officer of Syndax Pharmaceuticals, a seed-stage company formed to discover and develop novel therapeutics for the treatment of cancer via the combination of certain classes of drugs.
“Joanna has been a tremendous help to Nascent over the past year and I am delighted to welcome her as a Board member,” said Clive Reading, Nascent Chairman and Chief Executive Officer. “Her experience in developing oncology drugs and managing entrepreneurial companies adds an extra dimension to our Board.”
Prior to joining Syndax, Dr. Horobin was an Entrepreneur-in-Residence at MPM Capital, the world’s largest dedicated investor in life sciences. Previously, she held executive positions at several biotechnology companies including CombinatoRx, where as Chief Operating Officer she secured $70 million in venture financing and facilitated the transition of the company from a research to a development stage enterprise with multiple clinical programs. At EntreMed, as Executive Vice President, Commercial Development, Dr. Horobin played a major role in securing $80 million of financing as well as initiating clinical development of three angiogenesis inhibitors, Panzem(R), Endostatin and Angiostatin. From 1994 to 1998, Dr. Horobin was Vice President Oncology at Rhone Poulenc Rorer, where she introduced Taxotere(R) and Campto(R) to the market and helped to launch RPR as a global player in oncology.
Dr. Horobin earned her medical degree at the University of Manchester, England, and is a member of the Royal College of General Practitioners. In addition, she holds a Diploma in Pharmaceutical Medicine from the Royal College of Physicians.
About Nascent Pharmaceuticals, Inc.
Nascent Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company. Nascent has acquired compounds and technologies in the areas of ophthalmology and oncology that are in various stages of clinical and pre- clinical development. Nascent is currently seeking a co-development and commercialization partner for iDESTRIN. The company has offices in North Carolina and the San Francisco Bay Area. For more information, please visit our web site: www.nascentpharma.com .
Nascent Pharmaceuticals, Inc.
CONTACT: Clive Reading, Chief Executive Officer of NascentPharmaceuticals, Inc., +1-919-806-4569, or readingc@nascentpharma.com
Web site: http://www.nascentpharma.com/
